2-Acetyl-3-ethylpyrazine
(Synonyms: 2-乙酰基-3-乙基吡嗪) 目录号 : GC60469
2-Acetyl-3-ethylpyrazine是一种内源性代谢产物。
Cas No.:32974-92-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
2-Acetyl-3-ethylpyrazine is an endogenous metabolite.
| Cas No. | 32974-92-8 | SDF | |
| 别名 | 2-乙酰基-3-乙基吡嗪 | ||
| Canonical SMILES | CC(C1=NC=CN=C1CC)=O | ||
| 分子式 | C8H10N2O | 分子量 | 150.18 |
| 溶解度 | 储存条件 | 4°C, stored under nitroge | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 6.6587 mL | 33.2934 mL | 66.5868 mL |
| 5 mM | 1.3317 mL | 6.6587 mL | 13.3174 mL |
| 10 mM | 0.6659 mL | 3.3293 mL | 6.6587 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Developing a binuclear multi-target Bi(III) complex by optimizing 2-Acetyl-3-ethylpyrazine thiosemicarbazides
Eur J Med Chem 2019 Nov 15;182:111616.PMID:31425907DOI:10.1016/j.ejmech.2019.111616.
On the one hand, the multi-target agents have been promising for overcoming the deficiency of the single targeted anticancer metal agents, on the other hand, bismuth (Bi) complexes have shown significant antiproliferative activity and minimal side effects. Therefore, to develop the next-generation anticancer metal agents, we designed and synthesized four novel binuclear Bi(III) complexes by modifying the N-4 position of a series of 2-Acetyl-3-ethylpyrazine thiosemicarbazides, and then investigated their structure-activity relationships to human cancer cell lines, obtaining a lead Bi drug (C4) with significant antiproliferative activity to human bladder cancer cells (T24). C4 arrested the cell cycle in the S-phase by regulation of cyclin and cyclin-dependent kinases, and exerted a chemotherapeutic effect via multi-target mechanism including the activation of apoptotic and autophagic cell signaling pathways. Besides, C4 effectively inhibited metastasis of T24 cell. Our results suggested that C4 can be developed as a potential multi-target anticancer candidate.
Safety and efficacy of pyrazine derivatives including saturated ones belonging to chemical group 24 when used as flavourings for all animal species
EFSA J 2017 Feb 3;15(2):e04671.PMID:32625397DOI:10.2903/j.efsa.2017.4671.
Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of 22 compounds belonging to chemical group 24 (pyrazine derivatives). They are currently authorised as flavours in food. The FEEDAP Panel concludes that: 2,3-diethylpyrazine [14.005], 2-ethyl-3-methylpyrazine [14.006], 5,6,7,8-tetrahydroquinoxaline [14.015], 2,3,5,6-tetramethylpyrazine [14.018], 2,3,5-trimethylpyrazine [14.019], 2,5-dimethylpyrazine [14.020], 2,6-dimethylpyrazine [14.021], 2-ethylpyrazine [14.022], 2-ethyl-3,5-dimethylpyrazine [14.024], 2,5 or 6-methoxy-3-methylpyrazine [14.025], 2-methylpyrazine [14.027], acetylpyrazine [14.032], 6,7-dihydro-5-methyl-5H-cyclopenta(b)pyrazine [14.037], 2-isobutyl-3-methoxypyrazine [14.043], 2-Acetyl-3-ethylpyrazine [14.049], 2,3-dimethylpyrazine [14.050], 2,3-diethyl-5-methylpyrazine [14.056], 2-(sec-butyl)-3-methoxypyrazine [14.062], 3,(5- or 6-)-dimethyl-2-ethylpyrazine [14.100], 2-ethyl-3-methoxypyrazine [14.112] and 2-methoxy-3-methylpyrazine [14.126] are safe at the proposed maximum dose level (0.5 mg/kg complete feed) as feed for cattle, salmonids and non-food-producing animals, and at the proposed normal use level of 0.1 mg/kg complete feed for pigs and poultry; 5-methylquinoxaline [14.028] are safe only at concentrations below the proposed use levels (0.08 mg/kg complete feed for cattle, salmonids and non-food-producing animals, and 0.05 mg/kg complete feed for pigs and poultry). No safety concern would arise for the consumer from the use of these compounds up to the highest proposed level in feeds. Hazards for skin and eye contact, and respiratory exposure are recognised for the majority of the compounds under application. Most are classified as irritating to the respiratory system. The proposed maximum use levels in feed are unlikely to have detrimental effects on the terrestrial and fresh water compartments. Because all the compounds under assessment are used in food as flavourings and their function in feed is essentially the same as that in food, no further demonstration of efficacy is necessary.
Novel Brain-Tumor-Inhibiting Copper(II) Compound Based on a Human Serum Albumin (HSA)-Cell Penetrating Peptide Conjugate
J Med Chem 2019 Dec 12;62(23):10630-10644.PMID:31693353DOI:10.1021/acs.jmedchem.9b00939.
It is a great challenge to design drugs that penetrate the blood-brain barrier to inhibit brain tumor growth by acting against multiple targets and also improve their delivery efficacy and targeting ability to cancer cells. To overcome the above problems, we designed a multitarget metal agent for treating brain tumors based on an human serum albumin (HSA)-cell penetrating peptide conjugate. Thus, we rationally screened copper (Cu) and 2-Acetyl-3-ethylpyrazine thiosemicarbazones to synthesize six compounds, and we investigated their structure-activity relationships and confirmed multiple mechanisms for brain glioma cells. The HSA-6b complex structure indicated that 6b binds to the IIA subdomain of HSA and His242 replaces the Br ligand in 6b in coordination with Cu2+. In vivo data suggested that both 6b and the HSA-6b-peptide conjugate penetrate the blood-brain barrier and inhibit brain tumor growth with few side effects. Furthermore, the HSA-peptide conjugate also improved the delivery efficacy and targeting ability of 6b in vivo.